Activates local immunity in viral entry sites1
Immune cells may stop viruses decreasing the risk of their proliferation1
For prevention and treatment of viral infections
Polyoxidonium® can:
activate body's immune response to viruses1
increase body's resistance to infections of any etiology1
decrease disease duration and severity2,4
Polyoxidonium® is approved by MH RF or performance of III phase international multicenter placebo-controlled clinical study (IMCS) of efficacy in the treatment of COVID-19 coronavirus infection.
Polyoxidonium® is included into Slovak clinical recommendations on COVID-19 treatment.
Polyoxidonium® is included into methodical recommendations on ARVI and flu treatment during the COVID-19 epidemy.
midical pack

Polyoxidonium® is included into guidelines and supported by leading scientific organizations

medical pack
For respiratory viral infections prevention:
  • children aged 3 years and older
    ½ of a tablet 1 time a day for 7 days
  • children aged 10 years and older
    1 tablet 1 time a day for 7 days
  • adults
    1 tablet 1 time a day for 10 days
medical pack

For respiratory viral infections treatment1:

  • children aged 3 years and older
    ½ of a tablet 2 times a day for 7 days
  • children aged 10 years and older
    1 tablet 2 times a day for 7 days
  • adults
    1 tablet 2 times a day for 7 days

Polyoxidonium® to combat respiratory viral infections


Polyoxidonium® can have a combined effect on the course of respiratory viral infections1:

  • can decrease disease severity3,
  • decreases inflammation4,
  • boosts immunity and reduces the number of repeated cases of ARVI6.
In case of any drug-associated adverse events or any claims to the product quality, please contact NPO Petrovax Pharm, LLC:
Or use pharmacovigilance feedback page:


  1. Patient information leaflet for Polyoxidonium®.
  2. Malanicheva, T.G., Agafonova, E.V. (2018). The effectiveness of immunomodulatory therapy of community-acquired pneumonia in frequently ill children. Children Infections, 17(4), 38–43.
  3. Garaschenko, T.I., Karneeva, O.V., Tarasova, G.D., et al. (2020). Influence of local application of Polyoxidonium® on symptoms and course of acute respiratory viral infection in children: results of multicenter double-blind placebo-controlled study. Consilium Medicum, 22(3), 80–86.
  4. Karaulov, A.V., Gorelov, A.V. (2019). The use of azoximer bromide for treatment of inflammatory infections of respiratory system in children: a meta-analysis of controlled clinical studies. Journal of Infectology, vol. 11, No. 4, 31–41.
  5. Pruzinec, P., Chirun, N., Sveikata, A. (2018). The safety profile of Polyoxidonium® in daily practice: results from postmarketing safety study in Slovakia. Immunotherapy, 10(2), 1–7.
  6. Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.
Asc a question
If you have a non-standard question, please contact us. Attention! Referring to the site is not a substitute for consulting a doctor.
'raketa:form' is not a component
Asc a question
The question has been successfully sent, we will contact you shortly

The information posted in this section is intended for medical and / or pharmaceutical professionals. Please confirm that you are a professional in the respective field.